Literature DB >> 19084398

Canine inflammatory myopathy associated with Leishmania Infantum infection.

Orlando Paciello1, Gaetano Oliva, Luigi Gradoni, Laura Manna, Valentina Foglia Manzillo, Slawomir Wojcik, Francesca Trapani, Serenella Papparella.   

Abstract

Inflammatory myopathy associated with several infectious diseases occurs in dogs including those caused by Toxoplasma gondii, Neospora caninum, Ehrlichia canis and Hepatozoon canis. However, muscle disease due to Leishmania infection has been poorly documented. The aim of this study was to examine the distribution and types of cellular infiltrates and expression of MHC class I and II in muscle biopsies obtained from 15 male beagle dogs from a breeder group with an established diagnosis of leishmaniasis. Myopathic features were characterized by necrosis, regeneration, fibrosis and infiltration of mononuclear inflammatory cells consisting of lymphocytes, plasma cells and histiocytes. The predominant leukocyte populations were CD3+, CD8+ and CD45RA+ with lesser numbers of CD4+ cells. Many muscle fibers had MHC class I and II positivity on the sarcolemma. There was a direct correlation between the severity of pathological changes, clinical signs, and the numbers of Leishmania amastigotes. Our studies provided evidence that: 1) Leishmania should be considered as a cause of IM in dogs; 2) Leishmania is not present within muscle fibers but in macrophages, and that 3) the muscle damage might be related to immunological alterations associated with Leishmania infection. Leishmania spp. should also be considered as a possible cause in the pathogenesis of human myositis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19084398     DOI: 10.1016/j.nmd.2008.10.013

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  7 in total

Review 1.  Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus Syrian hamster model.

Authors:  Ana Nieto; Gustavo Domínguez-Bernal; José A Orden; Ricardo De La Fuente; Nadia Madrid-Elena; Javier Carrión
Journal:  Vet Res       Date:  2011-02-23       Impact factor: 3.683

2.  Clinical features of idiopathic inflammatory polymyopathy in the Hungarian Vizsla.

Authors:  Anna Tauro; Diane Addicott; Rob D Foale; Chloe Bowman; Caroline Hahn; Sam Long; Jonathan Massey; Allison C Haley; Susan P Knowler; Michael J Day; Lorna J Kennedy; Clare Rusbridge
Journal:  BMC Vet Res       Date:  2015-04-21       Impact factor: 2.741

3.  Immunopathological Features of Canine Myocarditis Associated with Leishmania infantum Infection.

Authors:  Alessandro Costagliola; Giuseppe Piegari; Iwona Otrocka-Domagala; Davide Ciccarelli; Valentina Iovane; Gaetano Oliva; Valeria Russo; Laura Rinaldi; Serenella Papparella; Orlando Paciello
Journal:  Biomed Res Int       Date:  2016-06-19       Impact factor: 3.411

4.  The correlation between cardiac and skeletal muscle pathology in animal models of idiopathic inflammatory myopathies.

Authors:  Francesco Prisco; Serenella Papparella; Orlando Paciello
Journal:  Acta Myol       Date:  2020-12-01

5.  Leishmania spp.-Infected Dogs Have Circulating Anti-Skeletal Muscle Autoantibodies Recognizing SERCA1.

Authors:  Francesco Prisco; Davide De Biase; Giuseppe Piegari; Francesco Oriente; Ilaria Cimmino; Valeria De Pasquale; Michele Costanzo; Pasquale Santoro; Manuela Gizzarelli; Serenella Papparella; Orlando Paciello
Journal:  Pathogens       Date:  2021-04-12

6.  Vacuolar myopathy in a dog resembling human sporadic inclusion body myositis.

Authors:  Jason King; Richard A LeCouteur; Monica Aleman; D Colette Williams; Peter F Moore; Ling T Guo; Andrew P Mizisin; G Diane Shelton
Journal:  Acta Neuropathol       Date:  2009-08-29       Impact factor: 17.088

7.  Immunopathology of Parasitic Infections and Therapeutic Approaches in Humans and Animals.

Authors:  Orlando Paciello; Chiara Palmieri; Iwona Otrocka-Domagala; Laura Rinaldi; Jorge Morales-Montor; Peter Geldhof
Journal:  Biomed Res Int       Date:  2016-08-31       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.